

Giuseppe A Ramirez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3779042/publications.pdf>

Version: 2024-02-01

123
papers

3,095
citations

212478

28
h-index

214428

50
g-index

129
all docs

129
docs citations

129
times ranked

5390
citing authors

#	ARTICLE	IF	CITATIONS
1	Colchicine treatment in community healthcare setting to prevent severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e198-e198.	0.5	6
2	Outcomes of noninvasive ventilation as the ceiling of treatment in patients with COVID-19. <i>Panminerva Medica</i> , 2022, 64, .	0.2	13
3	Platelet Phagocytosis via P-selectin Glycoprotein Ligand 1 and Accumulation of Microparticles in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2022, 74, 318-328.	2.9	12
4	Hypersensitivity reactions to iodinate contrast media in Italy: a retrospective study. Characteristics of patients and risk factors. <i>European Annals of Allergy and Clinical Immunology</i> , 2022, 54, 60.	0.4	8
5	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	2.9	78
6	Influence of reduced muscle mass and quality on ventilator weaning and complications during intensive care unit stay in COVID-19 patients. <i>Clinical Nutrition</i> , 2022, 41, 2965-2972.	2.3	32
7	Testosterone in males with COVID-19: A 7-month cohort study. <i>Andrology</i> , 2022, 10, 34-41.	1.9	57
8	Continuous positive airway pressure and pronation outside the Intensive Care Unit in COVID-19 acute respiratory distress syndrome. <i>Minerva Medica</i> , 2022, 113, .	0.3	30
9	Biobanking for COVID-19 research. <i>Panminerva Medica</i> , 2022, 64, .	0.2	36
10	Selective serotonin reuptake inhibitors and fractures in older nursing home residents: Data from the INCUR study. <i>Maturitas</i> , 2022, 158, 37-39.	1.0	1
11	A novel evidence-based algorithm to predict thromboembolism in patients with COVID-19: preliminary data from a single-center cohort. <i>Minerva Medica</i> , 2022, 113, .	0.3	6
12	Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis. <i>Clinical Immunology Communications</i> , 2022, 2, 23-29.	0.5	2
13	Frailty as a predictor of mortality in COVID-19 patients receiving CPAP for respiratory insufficiency. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 945-949.	1.4	4
14	Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study. <i>Nutrients</i> , 2022, 14, 1513.	1.7	13
15	Clinical features and outcomes of COVID-19 in patients with IgG4-related disease: a European multi-centre study. <i>Rheumatology</i> , 2022, 61, e109-e111.	0.9	4
16	Chromogranin A plasma levels predict mortality in COVID-19. <i>PLoS ONE</i> , 2022, 17, e0267235.	1.1	9
17	The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study. <i>Vaccines</i> , 2022, 10, 663.	2.1	10
18	Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMILE) Cohort. <i>Journal of Clinical Medicine</i> , 2022, 11, 3587.	1.0	7

#	ARTICLE	IF	CITATIONS
19	Resting state network functional connectivity abnormalities in systemic lupus erythematosus: correlations with neuropsychiatric impairment. <i>Molecular Psychiatry</i> , 2021, 26, 3634-3645.	4.1	14
20	Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part). <i>Journal of Autoimmunity</i> , 2021, 107, 102787.	0.9	8
21	Urgent manifestations of immunoglobulin G₄-related disease. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 48-51.	0.6	6
22	Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. <i>Clinical Microbiology and Infection</i> , 2021, 27, 451-457.	2.8	243
23	Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?. <i>Rheumatology</i> , 2021, 60, 1376-1386.	0.9	11
24	Neutrophil Extracellular Traps in the Autoimmunity Context. <i>Frontiers in Medicine</i> , 2021, 8, 614829.	1.2	25
25	Severely low testosterone in males with COVID-19: A case-control study. <i>Andrology</i> , 2021, 9, 1043-1052.	1.9	100
26	Baseline characteristics of systemic lupus erythematosus patients included in the Lupus Italian Registry of the Italian Society for Rheumatology. <i>Lupus</i> , 2021, 30, 1233-1243.	0.8	3
27	Catastrophic antiphospholipid syndrome presenting with aortic barrage: case report and review of the literature. <i>Lupus</i> , 2021, 30, 1005-1009.	0.8	0
28	POS1247...CLINICAL FEATURES AND OUTCOMES OF COVID-19 IN PATIENTS WITH IGG4-RELATED DISEASE. A COLLABORATIVE EUROPEAN MULTI-CENTRE STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 907.1-907.	0.5	0
29	Correspondence on Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort™. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e159-e159.	0.5	18
30	Prognostic Factors and Long-Term Outcome with ANCA-Associated Kidney Vasculitis in Childhood. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1043-1051.	2.2	19
31	POS0693...EFFICACY AND SAFETY OF BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS IN REAL-LIFE SETTING: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC, PROSPECTIVE COHORT. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 594-595.	0.5	0
32	Six-month respiratory outcomes and exercise capacity of COVID-19 acute respiratory failure patients treated with continuous positive airway pressure. <i>Internal Medicine Journal</i> , 2021, 51, 1810-1815.	0.5	12
33	POS0726...POST-TRAUMATIC STRESS DISORDER AND QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS. A CROSS SECTIONAL WEB SURVEY-BASED STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 613.1-613.	0.5	0
34	Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia. <i>Current Rheumatology Reports</i> , 2021, 23, 52.	2.1	6
35	Utility of the 2019 ACR/EULAR classification criteria for the management of patients with IgG4-related disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 761-765.	1.6	6
36	Drug reaction with eosinophilia and systemic symptoms (DRESS) in patients with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1190-1192.	2.8	9

#	ARTICLE	IF	CITATIONS
37	Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine. <i>Vaccine</i> , 2021, 39, 6464-6469.	1.7	8
38	Serum IgG4 level predicts COVID-19 related mortality. <i>European Journal of Internal Medicine</i> , 2021, 93, 107-109.	1.0	21
39	Thromboembolism risk among patients with diabetes/stress hyperglycemia and COVID-19. <i>Metabolism: Clinical and Experimental</i> , 2021, 123, 154845.	1.5	22
40	Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year. <i>Clinical Immunology</i> , 2021, 231, 108845.	1.4	14
41	Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3020-3023.	3.0	6
42	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLISS-LN). Results from a large, nationwide, multicentric cohort. <i>Journal of Autoimmunity</i> , 2021, 124, 102729.	3.0	23
43	Low incidence of intrauterine growth restriction in pregnant patients with systemic lupus erythematosus taking hydroxychloroquine. <i>Immunological Medicine</i> , 2021, 44, 204-210.	1.4	9
44	Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. <i>Rheumatology</i> , 2021, 60, 3176-3188.	0.9	9
45	Quantitative MRI adds to neuropsychiatric lupus diagnostics. <i>Rheumatology</i> , 2021, 60, 3278-3288.	0.9	5
46	Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases. <i>Vaccines</i> , 2021, 9, 1147.	2.1	8
47	Serum IgG4 elevation in hyper-inflamed COVID-19 patients. Author's reply. <i>European Journal of Internal Medicine</i> , 2021, , .	1.0	3
48	Subacute cutaneous lupus erythematosus induced by dupilumab: a novel possible association with specific pathogenetic mechanisms. <i>Italian Journal of Dermatology and Venereology</i> , 2021, , .	0.1	1
49	Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis. <i>Journal of Rheumatology</i> , 2020, 47, 377-386.	1.0	77
50	Structural and functional brain connectomes in patients with systemic lupus erythematosus. <i>European Journal of Neurology</i> , 2020, 27, 113.	1.7	18
51	Neonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives. <i>Pharmacological Research</i> , 2020, 152, 104583.	3.1	4
52	Diagnostic performance of aPS/PT antibodies in neuropsychiatric lupus and cardiovascular complications of systemic lupus erythematosus. <i>Autoimmunity</i> , 2020, 53, 21-27.	1.2	10
53	COVID-19: Pharmacology and kinetics of viral clearance. <i>Pharmacological Research</i> , 2020, 161, 105114.	3.1	17
54	Systemic lupus erythematosus and COVID-19: what we know so far. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-218601.	0.5	12

#	ARTICLE	IF	CITATIONS
55	Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. <i>Scientific Reports</i> , 2020, 10, 21291.	1.6	32
56	Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology. <i>Clinical and Molecular Allergy</i> , 2020, 18, 8.	0.8	25
57	Treating COVID-19 with colchicine in community healthcare setting. <i>Clinical Immunology</i> , 2020, 217, 108490.	1.4	69
58	Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. <i>Rheumatology</i> , 2020, 59, 2435-2442.	0.9	46
59	COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1150-1157.	1.6	52
60	IgG4-related disease and allergen-specific immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 631-633.	0.5	9
61	Pharmacological blockade of TNF \pm prevents sarcopenia and prolongs survival in aging mice. <i>Aging</i> , 2020, 12, 23497-23508.	1.4	30
62	FRI0183â€¦DISTINCTIVE TRAITS OF MYOCARDIAL INFLAMMATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A MULTICENTRE STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 675.2-675.	0.5	0
63	AB0512â€¦ALLERGIC PROFILE AND ALLERGEN-SPECIFIC IMMUNOTHERAPY IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A SINGLE CENTER OBSERVATIONAL STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1553.1-1554.	0.5	0
64	SAT0267â€¦ROLE OF AGGRESSIVE IMMUNOSUPPRESSION ON SUBGLOTTIC STENOSIS IN GRANULOMATOSIS WITH POLYANGIITIS: RETROSPECTIVE ANALYSIS OF A MONOCENTRIC COHORT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1076.1-1077.	0.5	0
65	AB1047â€¦IgG4-RELATED DISEASE PRESENTATION REQUIRES ADMISSION TO THE EMERGENCY DEPARTMENT IN THE MAJORITY OF CASES. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1814.1-1815.	0.5	0
66	SAT0243â€¦SUBPHENOTYPES IN POLYARTERITIS NODOSA (PAN): TARGET ORGAN ASSOCIATIONS OF A WORLDWIDE COLLABORATION STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1064-1065.	0.5	0
67	FRI0167â€¦LONG TERM CLINICAL OUTCOME IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS FOLLOWED FOR MORE THAN 20 YEARS IN THREE ITALIAN TERTIARY REFERRAL CENTERS: THE MILAN SYSTEMIC LUPUS ERYTHEMATOSUS CONSORTIUM (SMILE) COHORT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 667.1-668.	0.5	0
68	SAT0231â€¦MULTIDIRECTIONAL DYSFUNCTION OF THE IMMUNE RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1058-1058.	0.5	0
69	Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1752-1761.	0.9	15
70	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. <i>Nature Communications</i> , 2019, 10, 5120.	5.8	160
71	Misunderstandings Between Platelets and Neutrophils Build in Chronic Inflammation. <i>Frontiers in Immunology</i> , 2019, 10, 2491.	2.2	24
72	185.â€¦GENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE. <i>Rheumatology</i> , 2019, 58, .	0.9	0

#	ARTICLE	IF	CITATIONS
73	337.â€fMEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A SINGLE CENTRE REAL-LIFE EXPERIENCE. Rheumatology, 2019, 58, .	0.9	0
74	PTX3 Intercepts Vascular Inflammation in Systemic Immune-Mediated Diseases. Frontiers in Immunology, 2019, 10, 1135.	2.2	28
75	SAT0177â€f...CLINICAL AND EPIDEMIOLOGICAL RELEVANCE OF ALLERGY IN SYSTEMIC LUPUS ERYTHEMATOSUS: AN OBSERVATIONAL STUDY. , 2019, , .		0
76	SAT0204â€f...LUPUS LOW-DISEASE ACTIVITY STATE VS SLE RESPONDER INDEX IN A â€œREAL-LIFEâ€•SETTING. , 2019, , .		0
77	THU0005â€f...PTX3 AS A UNIVERSAL MARKER OF VASCULAR INFLAMMATION IN MULTIPLE IMMUNE-MEDIATED DISEASES. , 2019, , .		0
78	Under crossfire: thromboembolic risk in systemic lupus erythematosus. Rheumatology, 2019, 58, 940-952.	0.9	19
79	C3-glomerulopathy and MGUS: the skin beyond the kidney. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 187-188.	0.2	4
80	Diamine Oxidase Supplementation in Chronic Spontaneous Urticaria: A Randomized, Double-Blind Placebo-Controlled Study. International Archives of Allergy and Immunology, 2018, 176, 268-271.	0.9	29
81	The saga of atherothrombosis and T-cells: Looking for the lost prologue. International Journal of Cardiology, 2018, 259, 51-52.	0.8	1
82	Disease trends over time and CD4 + CCR5 + T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 53-63.	1.1	31
83	Genetics in systemic lupus erythematosus: entering the borough of cardiovascular risk. Annals of Translational Medicine, 2018, 6, S14-S14.	0.7	4
84	138â€fDisease trends and phenotypes among different age groups: a study in lupus. Rheumatology, 2018, 57, .	0.9	0
85	The TRPC6 intronic polymorphism, associated with the risk of neurological disorders in systemic lupus erythematosus, influences immune cell function. Journal of Neuroimmunology, 2018, 325, 43-53.	1.1	7
86	Eosinophils from Physiology to Disease: A Comprehensive Review. BioMed Research International, 2018, 2018, 1-28.	0.9	182
87	Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis. Science Translational Medicine, 2018, 10, .	5.8	118
88	The Neutrophilâ€™s Choice: Phagocytose vs Make Neutrophil Extracellular Traps. Frontiers in Immunology, 2018, 9, 288.	2.2	177
89	Ion Channels and Transporters in Inflammation: Special Focus on TRP Channels and TRPC6. Cells, 2018, 7, 70.	1.8	39
90	Analysis of the common genetic component of large-vessel vasculitides through a meta-ImmunoChip strategy. Scientific Reports, 2017, 7, 43953.	1.6	52

#	ARTICLE	IF	CITATIONS
91	FDG Uptake by Prosthetic Arterial Grafts in Large Vessel Vasculitis Is Not Specific for Active Disease. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 1042-1052.	2.3	31
92	ANCA-associated vasculitis in childhood: recent advances. <i>Italian Journal of Pediatrics</i> , 2017, 43, 46.	1.0	71
93	Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e394-e396.	1.7	10
94	Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. <i>Rheumatology</i> , 2017, 56, 2084-2092.	0.9	60
95	THU0331...Myeloperoxidase depletion is a selective feature of takayasu arteritis and predicts the clinical outcome. , 2017, , .		0
96	FRI0624...Structural MRI-based connectomics in SLE: a pilot study. , 2017, , .		0
97	FRI0357...Microparticles as a biomarker and a redox-dependent regulator of neutrophil activation and proteolytic activity in patients with systemic sclerosis. , 2017, , .		0
98	Bet on NETs! Or on How to Translate Basic Science into Clinical Practice. <i>Frontiers in Immunology</i> , 2016, 7, 417.	2.2	22
99	Editorial: Vascular Inflammation in Systemic Autoimmunity. <i>Frontiers in Immunology</i> , 2016, 7, 471.	2.2	0
100	Pauci-immune glomerulonephritis: the ANCA-negative side of the coin. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 5-7.	0.9	3
101	Drug induced exfoliative dermatitis: state of the art. <i>Clinical and Molecular Allergy</i> , 2016, 14, 9.	0.8	14
102	Juxta-vertebral lesions in granulomatosis with polyangiitis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 356-360.	1.6	11
103	IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 135-145.	0.6	106
104	Pathogenic Role of ANCA in Small Vessel Inflammation and Neutrophil Function. , 2016, , 43-50.		0
105	Pregnancy in Takayasu Arteritis Patients Exposed to Anti-Tumour Necrosis Factor (Anti-TNF)- α Therapy. <i>Gynecology and Obstetrics Research: Open Journal</i> , 2016, 2, 96-98.	1.6	0
106	Bortezomib in Type I Cryoglobulinemic Vasculitis: Are We Acting Too Late?. <i>Internal Medicine</i> , 2015, 54, 1119-1123.	0.3	12
107	Are atopy and eosinophilic bronchial inflammation associated with relapsing forms of chronic rhinosinusitis with nasal polyps?. <i>Clinical and Molecular Allergy</i> , 2015, 13, 23.	0.8	14
108	Beta-adducin and sodium-calcium exchanger 1 gene variants are associated with systemic lupus erythematosus and lupus nephritis. <i>Rheumatology International</i> , 2015, 35, 1975-1983.	1.5	7

#	ARTICLE	IF	CITATIONS
109	Plasma levels of M-CSF are increased in ANCA-associated vasculitides with active nephritis. Results in Immunology, 2015, 5, 33-36.	2.2	4
110	TRPC6 gene variants and neuropsychiatric lupus. Journal of Neuroimmunology, 2015, 288, 21-24.	1.1	15
111	Parietal and intravascular innate mechanisms of vascular inflammation. Arthritis Research and Therapy, 2015, 17, 16.	1.6	17
112	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	2.6	144
113	Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum. Clinical and Experimental Immunology, 2014, 175, 150-166.	1.1	29
114	Raoultella planticola-associated cholangitis and sepsis: a case report and literature review. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 911-913.	0.2	20
115	Choroidal Neovascularization in a Patient with Crohn's Disease. Case Reports in Ophthalmology, 2014, 5, 249-254.	0.3	1
116	Endothelin ETB1 receptor agonism as a new therapeutic strategy in pulmonary arterial hypertension and chronic heart failure. Medical Hypotheses, 2013, 81, 896-897.	0.8	2
117	Efficacy and toxicity of treatments for nephritis in a series of consecutive lupus patients. Autoimmunity, 2013, 46, 537-546.	1.2	7
118	The role of platelets in the pathogenesis of systemic sclerosis. Frontiers in Immunology, 2012, 3, 160.	2.2	35
119	Hypertension negatively affects the pregnancy outcome in patients with antiphospholipid syndrome. Lupus, 2012, 21, 810-812.	0.8	5
120	Platelet-leukocyte deregulated interactions foster sterile inflammation and tissue damage in immune-mediated vessel diseases. Thrombosis Research, 2012, 129, 267-273.	0.8	31
121	Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity, 2012, 45, 584-587.	1.2	94
122	A polymorphic challenge. Journal of Hematological Malignancies, 2012, 2, .	0.0	0
123	Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia. Arthritis and Rheumatism, 2012, 64, 854-865.	6.7	89